Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of VIAject and regular human insulin as prandial insulin in type 2 diabetes
2006-006600-11Phase 3Completed
- Sponsor
- Biodel Inc.
- Start
- Jan 2007
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of VIAject in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Biodel Inc. Primary endpoint: Change in HbA1c from baseline to end of study. Started Jan 2007; status: completed.
02
Drugs
VIAject
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2006-006600-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006600-11.